¤E¤Q¤E¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦Ò¥jÃD

(B) 1. ¤@¦ì46·³¤k©Ê¯f¤H¡A¦]µo¿N¡B¬È´H¡B¥k°¼¸y³¡¯kµh¦Ó¨Ó«æ¶E¡A°Ý¶E¥çµo²{ªñ¤é¦³ÀW§¿²{¶H¡A¸g§¿²GÀˬdµo²{¦³WBC>100/ HPF¡A§¿²G°ö¾i¤Î¦å²G°ö¾i§¡ªø¥XEnterococcus faecalis¡A¹ï©Ò´ú¸Õ¤§§Ü¥Í¯À§¡¨ã±Ó·P©Ê¡]susceptible¡^¡A½Ð°Ý¤U¦C¦óºØÃĪ«ªvÀø¤è¦¡¬O³Ì¦X¾A¤§¿ï¾Ü¡H
A.Cefazolin+gentamicin
B.Ampicillin+gentamicin
C.Trimethoprim¡þsulfamethoxazole
D.Ceftriaxone alone
E.Cefazolin alone
 
(A) 2. µû¦ôÃþ­·Àã©ÊÃö¸`ª¢¤§¯e¯f¬¡©Ê(disease activities),¤U¦C¨º¤@¶µ³Ì¤£¨ã¬¡©Ê«ü¼Ð?
A.Ãþ­·Àã¦]¤l¿@«×
B.¸~µÈÃö¸`¤§¼Æ¥Ø
C.ESR¤W¤Éµ{«×
D.¯f¤H¦Û¨­¤§ÄY­««×µû¦ô(patient's global assessment)
E.À£µhÃö¸`¤§¼Æ¥Ø
 
(B) 3. ¤U¦C¦³Ãö«ÕªùÁ³±Û±ìµß(Helicobacter pylori)ªº±Ô­z¡A¦óªÌ¥¿½T? 1.80%·P¬VªÌ·|¦³®ø¤Æ©Ê¼ìºÅ¡A2.°£µß«á¬ù60-75%ªº­GÂH½¤¬ÛÃö²O¤Ú²Õ´²O¤ÚÀù(mucosa-associated lymphoid tissue lymploma)¥i¥H±o¨ì½w¸Ñ¡A3.»P­G¶NªùÀùµo¥Í¦³Ãö¡A4.ÄÝ©ó¨ã¦³§¿¯ÀúC(urease)¤§­²Äõ¤ó³±©Êµß(Gram-negative bacteria)
A.1+3
B.2+4
C.1+4
D.3+4
E.1+2
 
(B) 4. ¦bÀR¯ß¦åºÞ¤º®ê¶ë¯fÅܤ¤¡A©Ò¿×Virchow's triad¥]¬A¦³¡G
A.hypercoagulability, thrombocytosis¤Îvenous stasis
B.hypercoagulability, venous stasis¤Îvascular injury
C.hypercoagulability, venous obstruction¤Îendothelial dysfunction
D.thrombocytosis, venous obstruction¤Îatrio-venous fistula
E.thrombocytosis, venous stasis¤Îvascular injury
 
(A) 5. ¤U¦C¦óºØ¯f¤H¤£¾A¦X±µºØ¬y·P¬Ì­](influenza vaccine)¡H
A.¹ï³JÃþ»s«~¹L±Ó
B.µÇ°IºÜ
C.¨xµw¤Æ
D.¿}§¿¯f
E.­÷¨Å¤§°ü¤k
 
(A) 6. 45·³¨k©Ê¥D¶D¤W¸¡µh¡A¨­ÅéÀˬdµo²{¦³»´«×µo¿N¡A¦åÀ£¥¿±`¡A¤W¸¡¦³À£µh¥~¡A¨ä¾lÀˬd¨ÃµL¯S®í¡A¸¡³¡¹q¸£Â_¼hÀˬdµo²{¥ªµÇ¤W¸¢¦³ 1 ­Ó 3 x 3 ¤½¤À¸~½F¡A½Ð°Ý±z¦p¦ó³B¸m ?
A.Àˬd 24 hr urine cortisol ©Mcatecholamine
B.¶i¦æ¹q¸£Â_¼h¾É¤Þ²Ó°w¬ï¨ë²Ó­M¾ÇÀˬd
C.¦w±ÆºÏ®¶Äá¼vÀˬd
D.Âश¥~¬ì¶}¤M¤Á°£
E.¦w±Æ 6 ­Ó¤ë«á¹q¸£Â_¼hÀˬd°lÂÜ
 
(C) 7. 60·³¤k©Ê¬ù15¦~«e¶EÂ_¦³²Ä2«¬¿}§¿¯f¡A¦¹«á¶}©lªA¥Î¤fªA­°¦å¿}ÃĪ«¡A¥Ø«eªA¥ÎGlimepiride 6 mg qd¡A pioglitazone 30 mg qd¡A metformin 850 mg tid¡C ¥D¶Dªñ3­Ó¤ë¨Ó¦å¿}±±¨î¤£¨}¥BÅé­«´î¤Ö3¤½¤ç¡A¯f¤H§_»{¶¼­¹¡B¹B°Ê²ßºD²§©ó©¹±`¡C¨­ÅéÀˬd¡G¦åÀ£135/85 mmHg ¡B PR 96/min ¡B regular¡A BMI 27¡A ¦¹¥~µL¯S®í¡C©â¦åÀˬdAC 220 mg/dL¡A PC 250 mg/dL ¡AHbA1C 9.0%¡ACholesterol 200 mg/dL ¡ALDL-C 100 mg/dL¡A HDL-C 35 mg/dL ¡ATG 300 mg/dL¡A BUN 35 mg/dL¡A Creatinine 1.2 mg/dL ¡ANa 135 mM¡A K 3.8 mM¡A Urinalysis ¡Gprotein++¡F¸g¦^ÅU¯f¤H¶¼­¹¤Î¹B°Ê¶q©|¥i¡C¤U¦C³B¸m¦óªÌ¾A©y¡G(1)¼W¥[¤fªA­°¦å¿}ÃĪ«¾¯¶q¤ÎºØÃþ¡A(2)µ¹¤©´îªÎÃĨÏBMI­°¦Ü23¡A(3)µ¹¤©ACEI(Angiotensin- Converting Enzyme Inhibitor)¡A(4)§ï¥Î¯Ø®q¯ÀªvÀø¡A(5)µ¹¤©statinªvÀø¨ÏLDL-C­°¦Ü70 mg/dL
A.1+2
B.2+3
C.3+4
D.4+5
E.5+1
 
(D) 8. ¤@¦ì41·³¤k©Ê¡A±w¦³ºC©ÊB«¬¨xª¢¨Ö¨xµw¤Æ¡A¦b¨Ò¦æÀˬd¤¤µo²{¦å²G¬Û¦p¤U¡G¦å¬õ¯À13.5 g/dL¡A¥Õ¦å²y4,150/£gL¤ÀÃþ¥¿±`¡A¦å¤pªO67,000/£gL¡C²£¥Í³oºØÅܤƳ̱`¨£ªº­ì¦]¬°¦ó¡H
A.Idiopathic thrombocytopenic purpura
B.Thrombotic thrombocytopenic purpura
C.Systemic lupus erythematosus
D.Hypersplenism
E.Human immunodeficiency virus infection
 
(E) 9. ¦³¤@¦ì45·³¨k©Ê¯f¤H¡A¦]µo¿N¤Î¤UªÏ³n²Õ´·P¬V¦Ó¦Ü«æ¶E³B´N¶E¡A·P¬V¯f¨_¤§Áw²G°ö¾iªø¥Xmethicillin-resistant Staphylococcus aureus¡]MRSA¡^¡A¤U¦C¦óºØÃĪ«¤£¾A¦X¥Î©óªvÀø¦¹¯f¤H¡H
A.Vancomycin
B.Teicoplanin
C.Linezolid
D.Daptomycin
E.Imipenem
 
(D) 10. ¤@22·³¨k©Ê¯f±w©ó³Ìªñ¨â­Ó¤ë¤º¦b¥kÀV³¡ªø¥X¤@13¤½¤À¸~½F¡A¤Á¤ùÀˬdÅã¥Ü¬°²O¤Ú½F lymphocytic lymphoma¡F¯f±w±µ¨ü¤Æ¾ÇªvÀø¡A©óªvÀø«á²Ä¤G¤Ñ¸~½F§Y©úÅãÁY¤p¡A¦ý¬OªvÀø«á²Ä¤T¤Ñ¯f±w§¿²G´î¤Ö¡A¦å²GÀˬd¬°«æ©ÊµÇ°IºÜ¡F¦¹¯f±w³Ì¤£¥i¯à¦X¨Ö¤U¦C¦óºØ¥NÁ²§±`¡H
A.¥NÁ©ʻĦå¯g (metabolic acidosis)
B.°ª¦å¹[¯g (hyperkalemia)
C.°ª¦åÁC¯g(hyperphosphatemia)
D.°ª¦å¶t¯g(hypercalcemia)
E.°ª§¿»Ä¦å¯g(hyperuricemia)
 
(D) 11. ¤@¦ì51·³¤k©Ê±`±`ı±o²´·ú¦³²§ª«·P¦³¤T¦~¤§¤[¡A¤]¦³»´·Lªº¤f°®¡C²z¾ÇÀˬdµo²{¨â²´¦³µ²½¤ª¢¤Î°®Àê¡C½Ð°Ý¤U¦C¦óºØÀˬd¹ï¨ä¶EÂ_³Ì¦³À°§U?
A.Slit lamp examination
B.Ophthalmoscopic examination
C.Rose-Bengal staining
D.Schirmer's test
E.Sialoscintigraph
 
(D) 12. ¤@¦ì22·³ªº¨k©Ê¦b¶]§¹°¨©ÔªQÁɶ]«á¡A³Q°e¨ì«æ¶E³B¨Ó¡A¥Lªº¥D¶D¬O·¥«×¤f´÷»PÀY·w¡C·í®É¦åÀ£¬°90/60 mmHg¡A¤U¦C¦U¶µÀËÅç¼Æ¾Ú³£¦³¥i¯à¡A°£¤F¡G
A.Hematocrit °ª©ó¥¿±`­È
B.Urine specific gravity >1.018
C.BUN/Cre ratio > 20
D.Urine osmolarity < 300 mosmol/L
E.Urine sodium < 20 mEq/L
 


< ¤E¤Q¤E¦~«×¸ÕÃD¥Ø¿ý >